The frequency and intensity of discussions around the transition from fee-for-service to value-based care continue to increase at the payer and provider level. Little has been said about how medical technology companies should navigate this coming change.
Into that vacuum has crept an abundance of misperceptions. Perhaps the most dangerous one is a belief that simply structuring the terms of contracts as performance and risk-share guarantees will lead to success.
Create a display name to comment
This name will appear with your comment